QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
QQQ   326.36 (+0.80%)
AAPL   136.87 (+3.67%)
MSFT   224.97 (+0.28%)
FB   272.87 (+2.02%)
GOOGL   1,884.15 (+0.22%)
AMZN   3,306.99 (+1.34%)
TSLA   844.99 (-0.64%)
NVDA   554.70 (+3.75%)
BABA   260.00 (-2.07%)
CGC   33.56 (-0.21%)
GE   11.07 (-2.81%)
MU   85.01 (+1.81%)
AMD   91.53 (+3.13%)
NIO   58.34 (+1.09%)
T   28.83 (-0.45%)
F   11.53 (+6.17%)
ACB   11.17 (-3.21%)
BA   207.41 (-1.91%)
DIS   171.28 (-1.36%)
NFLX   579.84 (-1.11%)
GILD   66.98 (-1.49%)
Log in
NASDAQ:MOR

MorphoSys Stock Forecast, Price & News

$29.86
-0.66 (-2.16 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.60
Now: $29.86
$30.45
50-Day Range
$27.39
MA: $28.35
$30.52
52-Week Range
$18.21
Now: $29.86
$35.73
Volume25,569 shs
Average Volume33,982 shs
Market Capitalization$3.93 billion
P/E Ratio142.20
Dividend YieldN/A
Beta1.03
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
MorphoSys logo

MarketRank

Overall MarketRank

0.40 out of 5 stars

Medical Sector

1685th out of 1,926 stocks

Pharmaceutical Preparations Industry

702nd out of 773 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MOR
CUSIPN/A
CIKN/A
Phone49 89 89927 0
Employees640

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80.43 million
Book Value$3.49 per share

Profitability

Net Income$-115,380,000.00

Miscellaneous

Market Cap$3.93 billion
Next Earnings Date3/17/2021 (Estimated)
OptionableNot Optionable
$29.86
-0.66 (-2.16 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys (NASDAQ:MOR) Frequently Asked Questions

How has MorphoSys' stock been impacted by COVID-19 (Coronavirus)?

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MOR stock has increased by 18.2% and is now trading at $29.86.
View which stocks have been most impacted by COVID-19
.

Is MorphoSys a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MorphoSys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MorphoSys?

Wall Street analysts have given MorphoSys a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MorphoSys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as MorphoSys' CEO?

1,448 employees have rated MorphoSys CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among MorphoSys' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for MorphoSys
.

How were MorphoSys' earnings last quarter?

MorphoSys AG (NASDAQ:MOR) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.02. The business had revenue of $25.71 million for the quarter, compared to the consensus estimate of $22.23 million. MorphoSys had a net margin of 8.76% and a return on equity of 4.51%.
View MorphoSys' earnings history
.

What guidance has MorphoSys issued on next quarter's earnings?

MorphoSys issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, November, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370.446-382.132 million, compared to the consensus revenue estimate of $428.92 million.

Who are some of MorphoSys' key competitors?

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 55)
  • Mr. Jens H. Holstein, CFO & Member of the Management Board (Age 57)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 58)
  • Mr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 48)
  • Mr. Klaus De Wall, Head of Accounting & Tax
  • Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban, Head of Discovery Alliances & Technologies
  • Dr. Julia Neugebauer Ph.D., Director of Investor Relations
  • Dr. Armin Weidmann, Head of Compliance and Quality Assurance
  • Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 50)

When did MorphoSys IPO?

(MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

Who are MorphoSys' major shareholders?

MorphoSys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include OneAscent Financial Services LLC (0.01%).

Which major investors are buying MorphoSys stock?

MOR stock was purchased by a variety of institutional investors in the last quarter, including OneAscent Financial Services LLC.

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $29.86.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $3.93 billion and generates $80.43 million in revenue each year. The company earns $-115,380,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. MorphoSys employs 640 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company can be reached via phone at 49 89 89927 0 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.